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 INTRODUCTION 
 The World Health Organization (WHO) recommends that 
artemisinin-based combination therapies (ACTs) be used as 
first-line treatment of uncomplicated  Plasmodium falciparum 
malaria. 1 Treatment with ACTs is currently considered more 
effective than available non-artemisinin regimens, 2 resulting 
in faster symptomatic improvement and parasite clearance 1, 3 
and a reduction in gametocyte carriage, which could help to 
reduce malaria transmission. 1, 4– 6 
 In 2004, artemether-lumefantrine (AL, Coartem ® , Novartis 
Pharma AG, Basel, Switzerland) became the first ACT to be 
pre-qualified by WHO, and it is now used as first-line treat-
ment for uncomplicated  Plasmodium falciparum malaria in 
many regions worldwide. 7 The combination of artemether, 
which rapidly reduces parasite biomass, 8 with longer-acting 
lumefantrine, capable of eliminating residual parasites, 9 has 
proven to be highly effective in achieving parasitologic cure, 
symptom relief, 10– 15 and reduction of gametocyte carriage. 15, 16 
Typically, although with uncommon exceptions, 17 the 28-day 
parasitologic cure observed after AL therapy exceeded 95% 
in evaluable patients, 10– 15, 18– 20 meeting the WHO recommenda-
tion that cure rates for  P. falciparum malaria should be at least 
90% and preferably > 95%. 1 
 Although numerous randomized, controlled trials have con-
firmed the efficacy and safety of AL for treatment of uncom-
plicated  P. falciparum malaria in regions worldwide, 10– 14, 20– 28 
further analyses are desirable to ascertain whether efficacy 
is affected by different patient characteristics and to identify 
any infrequent safety concerns not detected within the limited 
sizes of individual trials. It is useful to examine data separately 
for adults and children because of differences between these 
groups in antimalarial immunity, 29, 30 transmission intensity, 
and disposition of some antimalarial drugs. 31 
 A recent Cochrane analysis evaluated the efficacy of ACTs 
for the treatment of uncomplicated  P. falciparum malaria 
and confirmed that the polymerase chain reaction (PCR)–
corrected parasitologic cure rate for AL at day 28 was > 95% 
in all the trials reviewed. 2 However, this analysis did not assess 
efficacy or safety outcomes separately among adults, children, 
or other subpopulations. Two pooled analyses of outcomes 
with AL have been performed in which children and adults 
were studied and the populations were defined by age, 18, 32 
but the cut-off point used (12 years) is not the one recom-
mended by the U.S. Food and Drug Administration (FDA) 
(i.e., 16 years). 6 
 We report efficacy and safety findings for AL in a post-hoc 
pooled analysis of data from the Novartis study database, which 
includes approximately 2,000 children and adults treated for 
uncomplicated  P. falciparum malaria during 1996–2007. The 
analysis population was derived from six studies undertaken 
in Asia and Africa and one study in patients from Europe and 
Colombia. This, it encompasses regions with varying endemic-
ity and transmission patterns. 
 MATERIALS AND METHODS 
 Study identification and design.  Data from clinical trials 
within the Novartis database were included in this unplanned 
pooled analysis if they enrolled patients treated with the 
recommended regimen of AL, administered twice a day for 
three days, and diagnosis of  P. falciparum malaria was based 
on microscopically confirmed evaluation of Giemsa-stained 
blood slides. Patients with severe or complicated malaria were 
not included in this analysis. Study B2303 used an investigator-
blinded design and A025 used a double-blind design; the 
remaining studies were open label. Six of the studies were 
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performed in malaria-endemic countries (studies A025, 
A026, A028, and A2412 in Thailand; A2403 and B2303 in 
Africa) 19, 26, 27, 33– 35 and one involved non-immune adult travelers 
in Europe and non-endemic regions of Colombia (A2401). 36 
The B2303 study was a randomized trial of the AL dispersible 
formulation versus AL tablets administered crushed: patients 
receiving the dispersible tablet were only included in the safety 
analyses (data from the B2303 study population confirmed 
equivalent efficacy and safety of the dispersible formulation 
and the crushed AL tablets). 34 The A2401 study included 
only adults. Studies A2403 and B2303 included only children 
(< 10 years of age and ≤ 12 years of age, respectively), and 
were both conducted in Africa (A2403: Kenya, Nigeria, 
and Tanzania; B2303: Benin, Kenya, Mali, Mozambique, 
and Tanzania). Three of the trials (A025, A026, and A028) 
took places during 1996–1999, and four took place during 
2001–2007 (A2401, A2403, B2303, and A2412). 
 In all studies, AL dosing was based on body weight: 
5–< 15 kg, 1 tablet per dose; 15–< 25 kg, 2 tablets per dose; 
25–< 35 kg, 3 tablets per dose; ≥ 35 kg, 4 tablets per dose. 
Patients who vomited the first dose within one hour of treat-
ment received a full replacement in all studies. The protocols 
of A2403 and B2303 specified that no more than two doses 
were to be replaced during the entire treatment period. 
 Six of the studies (A025, A026, A028, A2403, B2303, and 
A2401) recorded the 28-day parasitologic cure rate, corrected 
for re-infection by PCR in studies A025, A026, A028, A2403, 
and B2303 (as defined below under Data analysis), consis-
tent with draft guidance from the FDA. The PCR analysis was 
performed by analysis of size polymorphisms in the  P. falci-
parum genes encoding merozoite surface protein 2, merozo-
ite surface protein 1, and glutamate-rich protein 37, 38 in studies 
A025, A026, A028, A2403, and B2303. The PCR analysis was 
not performed in study A2401 because the patients were trav-
elers from regions to which malaria was not endemic and who 
were not at risk of a new infection. In this study, any recur-
ring parasites were regarded as recrudescences. These studies 
also recorded time to parasite and fever clearance, as defined 
below (see Data analysis). The remaining study (A2412) was 
an open-label, single-center, safety study and was included 
only in the safety analysis. Patients were followed-up for at 
least 28 days in all studies. Giemsa-stained thick blood smears 
were examined for asexual forms and gametocytes on days 
0–7 (day 0, first day of AL treatment) and thereafter on days 
14, 21, 28, and 42. All doses of AL were given under supervi-
sion in all studies except A2401. 
 Data analysis.  The main efficacy variable was the 28-day 
PCR-corrected parasitologic cure rate, which was defined as 
the proportion of patients with clearance of asexual parasitemia 
within 7 days of the first dose of AL and without subsequent 
recrudescence within 28 days. Recrudescence was defined as 
reappearance of the original parasite strain as confirmed by 
PCR-based genotyping. Other efficacy endpoints were the 
28-day non–PCR-corrected parasitologic cure rate, time to 
parasite clearance, time to fever clearance, and proportion of 
patients with gametocytes at specific time points. The times at 
which patients were assessed for parasite clearance and fever 
clearance varied between studies. The presence of gametocytes 
was recorded at baseline, > 0–72 hours, > 72 hours–day 7, and 
> day 7. 
 Safety data included the incidence, type, and study drug 
relationship of adverse events. Adverse events were defined 
as the appearance or worsening of any undesirable sign, symp-
tom, or medical condition after starting the study drug, even if 
the event was not considered to be related to the study drug, 
according to the International Conference on Harmonization 
Guidelines. A serious adverse event was defined as any untow-
ard medical occurrence that resulted in death, was life-threat-
ening, required inpatient hospitalization or prolongation of 
existing hospitalization, resulted in persistent or significant 
disability/incapacity, or was a congenital anomaly/birth defect. 
Other safety data included the incidence of death and serious 
adverse events, clinical laboratory assessments, and vital signs. 
The availability of laboratory data varied between studies in 
terms of parameters measured and time of sample collection. 
Creatinine clearance was used as a measure of renal function, 
and was calculated according to the Cockcroft-Gault formula 
in adults 39 and the Shull formula in children. 40 
 Statistical analysis.  Patients > 16 years of age were included 
in the adult analysis populations; patients ≤ 16 years of age 
were included in the pediatric analysis population. Efficacy 
and safety data were taken from the original study databases. 
 Efficacy analyses were based on the modified intent-
to-treat (mITT) population, which was generally defined as 
all patients with parasitologically confirmed  P. falciparum 
malaria who received at least one dose of study drug. This 
definition was selected to comply with FDA draft guidance. 41 
Efficacy analyses were also performed for evaluable patient 
populations. Definitions of the evaluable patient population 
differed between studies, but in general the evaluable popu-
lation included patients from the mITT population who took 
no other drug that had an anti-malarial effect, and had para-
site counts recorded up to day 28, or who discontinued the 
study because of an unsatisfactory therapeutic effect. A  post 
hoc analysis of the primary efficacy endpoint, 28-day PCR-
corrected parasitologic cure rate, was performed on the basis 
of data only from study A2401 by using the last observation 
carried forward technique. 
 The 28-day PCR-corrected parasitologic cure rate was also 
reported for subpopulations of the evaluable population, 
according to the following variables: 1) baseline parasite count 
(≤ 100,000/μL or > 100,000/μL); 2) sex; 3) baseline renal func-
tion based on creatinine clearance (normal > 80 mL/min; mild 
dysfunction ≥ 50–≤ 80 mL/min; moderate dysfunction ≥ 30–
< 50 mL/min; or severe dysfunction < 30 mL/min) (creati-
nine clearance < 30 mL/min is indicative of severe malaria in 
adults and no adult patients with severe renal dysfunction were 
recruited, in adherence with the studies’ exclusion criteria); 
4) baseline hepatic function (normal, total bilirubin ≤ upper 
limit of normal [ULN], and aspartate aminotransferase [AST] 
≤ ULN if available; mild dysfunction, total bilirubin ≤ ULN and 
AST > ULN, or total bilirubin > ULN – 1.5 × ULN; moderate 
dysfunction, total bilirubin > 1.5 – 3 × ULN; severe dysfunction, 
total bilirubin > 3 × ULN; if the AST value was missing, base-
line alanine aminotransferase value was used as per the criteria 
for AST); and 5) age (pediatric population only) (> 1 month–
≤ 2 years, > 2–≤ 16 years, or >12–≤ 16 years) and body weight 
(5–< 10 kg, 10–< 15 kg, 15–< 25 kg, 25–< 35 kg, or ≥ 35 kg). 
 All data are presented descriptively. One-sample 95% con-
fidence intervals (CIs) for the 28-day PCR-corrected cure 
rate were calculated by using the Pearson-Clopper method. 
Kaplan-Meier estimates of parasite clearance time and fever 
clearance time were calculated. Laboratory data are presented 
as standard summary statistics. Because of the variation 
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between studies in the time points used for laboratory eval-
uations and deviations from schedules, time windows were 
defined. If a patient had more than one value within a given 
interval, the mean was used for summarization. Summary sta-
tistics for laboratory data should be interpreted carefully in 
view of the variation between time windows and the numbers 
of patients with available data. Safety analyses were based on 
all randomized/enrolled patients who received at least one 
dose of study drug. Statistical analyses were performed using 
the SAS software system (SAS Institute, Cary, NC). 
 Study conduct.  All studies were conducted according to the 
Declaration of Helsinki, and informed consent was obtained 
from all patients (or parents/guardians where appropriate) 
according to appropriate institutional review board approval. 
 RESULTS 
 Populations for analysis and patient disposition.  For adults, 
the mITT population comprised 599 patients, of whom 437 took 
part in studies from malaria-endemic regions (studies A025, 
A026, and A028), and 162 were travelers from non-endemic 
regions (study A2401) ( Table 1 ). The evaluable population 
comprised 513 patients. Patients who received at least one 
dose of AL were considered for safety evaluation. The safety 
population comprised 647 patients, including 44 from study 
A2412, who were not included in the efficacy analysis because 
efficacy was addressed only as secondary objective and the 
study was stopped early for administrative reasons. For children 
(age ≤ 16 years), the mITT population comprised 877 patients 
and the evaluable population comprised 828 patients. A total 
of 1,333 pediatric patients were enrolled, but one patient in 
study A2412 did not receive AL and was excluded from the 
safety population. In study B2303, 447 patients received 
dispersible AL and were included in the safety, but not in the 
efficacy analysis. For children and adults, at least 83% of the 
mITT and safety populations completed the study ( Figure 1 ). 
 Patient demographics and baseline disease characteristics 
are shown in  Table 2 . Information on race was not collected 
in studies A025, A026, or A028, which studied populations 
in Thailand. In the pediatric population, more than 90% of 
patients were ≤ 12 years of age; almost half were 1 month–2 
years of age. A total of 29 children in the pediatric mITT pop-
ulation (3.3%), 28 patients in the pediatric evaluable popula-
tion (3.4%), and 36 patients in the pediatric safety population 
(2.7%) were 1–6 months of age. Approximately 90% of adults 
and children for whom parasite counts were available had a 
count ≤ 100,000/μL. 
 Exposure to AL.  The full recommended regimen of AL 
was taken by 96.9% of adults (n = 627) and 97.1% of children 
(n = 1,332) (safety populations). Seven adults (1.1%) and 140 
children (10.5%) vomited at least one dose of AL. 
 Parasitologic cure.  Parasitologic cure rates on day 28 among 
the pooled efficacy population are summarized in  Table 3 . In 
adults, the 28-day PCR-corrected parasitologic cure rate was 
97.1% (495 of 510; 95% CI = 95.2–98.3%) in the evaluable 
population and 83.4% (499 of 598; 95% CI = 80.2–86.3%) in 
the mITT population. The difference in results was caused 
primarily by study A2401, the only study of non-immune 
travelers, in which a large number of patients did not undergo 
parasitologic assessments as scheduled. In this study, 33 of 
the 42 patients showed treatment failure. These results were 
caused by missing parasite assessments at day 28; negative 
blood smears were available at earlier time points for 27of 
these persons. An additional five treatment failures were 
so-classified because the patients received other antimalarial 
medications. Thus, in study A2401, the mITT cure rate was 
74.1% (120 of 162; 95% CI = 66.6–80.6%), and the evaluable 
cure rate was 96.0% (119 of 124; 95% CI = 90.8–98.7%); a 
 post hoc analysis using the last observation carried forward 
technique showed a 90.7% cure rate (147 of 162). 
 One potential explanation for treatment failures may be 
underdosing of larger patients. In the evaluable population 
of study A2401, the cure rate was 93.0% (66 of 71; 95% CI = 
84.3–97.7%) in patients weighing ≥ 70 kg versus 100% (52 
of 52; 95% CI = 93.2–100%) in patients < 70 kg. Of the five 
patients weighing ≥ 70 kg who were classified as treatment 
failures, one patient discontinued treatment after the second 
dose because of signs and symptoms of severe malaria that 
were already present at baseline, one missed an assessment at 
day 6 but was clear of parasites at day 7, and three had recru-
descence during days 21 and 28. In addition, of four patients 
with body weights >100 kg, three were clear of parasites at day 
28, and one did not have a day 28 blood assessment, but was 
parasite free at 58 and 154 hours. 
 In the pediatric population, the 28-day PCR-corrected par-
asitologic cure rate was 97.3% (792 of 814; 95% CI = 95.9–
98.3%) in the evaluable population and 93.4% (798 of 854; 
95% CI = 91.6–95.0%) in the mITT population. No differ-
ences were observed between age groups or different body 
weight categories, including patients ≤ 2 years of age or those 
weighing < 10 kg ( Table 4 ). 
 Baseline parasite density did not appear to affect the 28-day 
PCR-corrected cure rate in either adults or children ( Table 4 ). 
There was a trend towards a lower cure rate in patients with 
impaired hepatic function in the adult and pediatric popula-
tions, but there were few patients with moderate/severe impair-
ment (only 13 adults and 2 children with severe impairment), 
which limited the reliability of these findings ( Table 4 ). 
 Parasite clearance time.  The median time to parasite 
clearance was 42.3 hours (95% CI = 41.5–43.2 hours) in the 
adult mITT population, and parasite clearance was achieved 
within 48 hours in 78.6% of patients ( Table 5 ). For children, 
the median parasite clearance time for the mITT population 
was 35.3 hours (95% CI = 31.7–35.7 hours), and 90.3% of 
patients showed parasite clearance in ≤ 48 hours. In the study 
A2401 mITT analysis, the median time to parasite clearance 
was 41.8 hours (95% CI = 40.3–43.8 hours), and 108 (066.7%) 
of 162 patients showed parasite clearance ≤ 48 hours. 
 Fever clearance time.  In adults, the median time to fever 
clearance was 28.5 hours (95% CI = 22.3–34.0 hours). Median 
time to fever clearance was shorter in patients with a baseline 
parasite count ≤ 100,000/μL (n = 464, 22.1 hours; 95% CI = 
21.2–24.0 hours) compared with those with a baseline count 
> 100,000/μL (n = 34, 43.1 hours; 95% CI = 21.7–45.9 hours). 
The median fever clearance time in children (7.9 hours; 95% 
CI = 7.9–8.0 hours) was markedly shorter than that in adults 
(28.5 hours; 95% CI = 22.3–34.0 hours). As in adults, a low 
baseline  P. falciparum count (≤ 100,000/μL) was associated 
with slightly shorter fever clearance time (n = 788, 7.9 hours; 
95% CI = 7.8–8.0 hours) compared with those with parasite 
counts > 100,000/μL (n = 88, median 11.3 hours; 95% CI = 
7.9–23.4 hours). For study A2401, the median time to fever 
clearance among patients with fever at baseline was 36.5 hours 
(95% CI = 27.8–39.5 hours in the mITT population). 
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 Gametocyte carriage.  The proportion of adult patients with 
 P. falciparum gametocytes at baseline was 9.7% (58 of 596), 
which decreased to 4.2% (23 of 554) after day 7 ( Table 5 ). 
Among children, 45 (5.1%) of 877 patients had gametocytes 
at baseline and 8 (0.9%) of 846 patients had gametocytes 
after day 7. For study A2401, 11.9% (19 of 160) and 1.4% (2 
of 139) of patients had gametocytes at baseline and after day 
7, respectively. Primaquine, which has gametocytocidal activity 
and could be prescribed at the discretion of the investigator, 42 
was administered to less than 1% of the patients, mostly after 
day 7 to treat concomitant  P. vivax infections or to eliminate 
 P. falciparum gametocytes. 
 Adverse events in adults.  One or more adverse events 
were reported by 557 (86.1%) of 647 adult patients. The 
most frequently reported adverse events were non-specific 
(headache, anorexia, dizziness, asthenia, arthralgia, myalgia, 
and nausea) and consistent with symptoms of acute malaria 
( Table 6 ). Adverse events potentially related to hypersensitivity 
reactions were reported by 4.0% of adults (rash = 3.2%, 
urticaria = 0.6%, facial edema = 0.2%). These adults showed an 
incidence of 2.8% during days 0–3 of treatment and 1.0% during 
days 4–10 of treatment ( Table 7 ). Nervous system disorders, 
mainly headache (55.6%) and dizziness (39.1%), occurred in 
59.7% of adults. These results are also consistent with malaria 
symptoms. Ear and labyrinth disorders were reported for 29 
patients (4.5%), of whom 21 experienced vertigo. Prolonged 
QT interval on electrocardiogram was reported for two 
adult patients (0.3%); however, syncope, sudden cardiac 
death, seizure, or significant ventricular arrhythmias was not 
reported for these patients. One adult patient (1 of 647, 0.2%) 
stopped treatment prematurely because of adverse events 
(mild abdominal pain/diarrhea). 
 No adult patient died. Nine patients (1.4%) experienced 
22 serious adverse events. No type of serious adverse event 
occurred in more than one patient except for  P. falciparum 
infection, which was reported by investigators as a serious 
adverse event in two patients. Of the 22 serious adverse events, 
18 occurred in study A2401, in which prolongation of hospital-
ization required a classification of serious adverse event. There 
were no cases of urticaria or anaphylactoid reaction reported 
 F igure 1.  Patient disposition for adults and children in the study of artemether-lumefantrine for treatment of uncomplicated  Plasmodium 
falciparum malaria. 
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 Table 2 
 Demographics and baseline disease characteristics of the study populations for patients treated with artemether-lumefantrine for uncomplicated 
 Plasmodium falciparum malaria * 
Characteristic
Adults Children
Efficacy mITT population (n = 599) Safety population (n = 647) Efficacy mITT population (n = 877) Enrolled population (n = 1,333 † )
Male sex, no. (%) 434 (72.5) 472 (73.0) 476 (54.3) 711 (53.3%)
Age (years)
 Mean ± SD 31.2 ± 11.5 31.0 ± 11.4 4.2 ± 4.1 4.1 ± 3.7
 Range 17–71 ‡ 17–71 § 0–16 0–16
 > 0 to ≤ 2, no. (%) – – 410 (46.8) 587 (44.0)
 > 2 to ≤ 12, no. (%) – – 410 (46.8) 680 (51.0)
 > 12 to ≤ 16, no. (%) – – 57 (6.5) 66 (5.0)
Race, no. (%)
 Caucasian 77 (12.9) 80 (12.4) 0 0
 Black 40 (6.7) 40 (6.2) 762 (86.9) 1,209 (90.7)
 Asian 0 44 (6.8) 0 9 (0.7)
 Other 45 (7.5) 45 (7.0) 0 0
 Not collected 437 (73.0) 438 (67.7) 115 (13.1) 115 (8.6)
Body weight (kg)
 Mean ± SD 57.4 ± 13.4 ¶ 57.0 ± 13.2 15.6 ± 9.1 15.3 ± 8.4
 Range 34–119 ¶ 34–119# 5.0–58.0 5.0–58.0
 5–< 10, no. (%) – – 238 (27.1) 323 (24.2)
 10–< 15, no. (%) – – 309 (35.2) 498 (37.4)
 15–< 25, no. (%) – – 217 (24.7) 361 (27.1)
 25–< 35, no. (%) – – 57 (6.5) 87 (6.5)
 ≥ 35, no. (%) – – 56 (6.4) 64 (4.8)
 P. falciparum parasite count (asexual forms/μL)
 Median 4,618 5,236 23,762 24,178
 Range 13–464,880 0–464,880 188–628,571 0–628,571
 ≤ 100,000, no. (%) 464 (77.5) 505 (78.1) 786 (89.6) 1,183 (88.7)
 <2,000, no. (%) 163 (27.2) 176 (27.2) 44 (5.0) 50 (3.8)
 2,000–< 5,000 90 (15.0) 92 (14.2) 112 (12.8) 165 (12.4)
 5,000–< 15,000 66 (11.0) 92 (14.2) 194 (22.1) 276 (20.7)
 15,000–< 50,000 98 (16.4) 110 (17.0) 262 (29.9) 440 (33.0)
 50,000–< 100,000 47 (7.8) 51 (7.9) 174 (19.8) 252 (18.9)
 > 100,000, no. (%) 34 (5.7) 37 (5.7) 91 (10.4) 147 (11.0)
 None, no. (%) 0 4 (0.6) 0 1 (0.1)
 Missing/different unit, no. (%) 101 (16.9) 101 (15.6) 0 2 (0.2)
Body temperature (°C)
 Mean ± SD 37.9 ± 1.1 37.8 ± 1.1 38.2 ± 1.0 38.2 ± 1.1
 < 37.5, no. (%) 235 (39.2) 267 (41.3) 164 (18.7) 301 (22.6)
 37.5–< 39.0, no. (%) 243 (40.6) 255 (39.4) 485 (55.3) 709 (53.2)
 ≥ 39.0, no. (%) 121 (20.2) 125 (19.3) 227 (25.9) 319 (23.9)
 Missing, no. (%) 0 0 1 (0.1) 4 (0.3)
Renal function at baseline ** 
 Normal, no. (%) 223 (37.2) 225 (34.8) 184 (21.5) 326 (24.5) †† 
 Mild dysfunction, no. (%) 143 (23.9) 143 (22.1) 321 (36.6) 510 (38.3) †† 
 Moderate dysfunction, no. (%) 9 (1.5) 10 (1.5) 191 (21.8) 292 (21.9) †† 
 Severe dysfunction, no. (%) 0 (0) 0 (0) 92 (10.5) 102 (7.7) †† 
 Missing, no. (%) 224 (37.4) 269 (41.6) 89 (10.1) 102 (7.7) †† 
Hepatic function at baseline ‡‡ 
 Normal, no. (%) 164 (27.4) 167 (25.8) 144 (16.4) 144 (10.8)
 Mild dysfunction, no. (%) 121 (20.2) 121 (18.7) 170 (19.4) 170 (12.8)
 Moderate dysfunction, no. (%) 60 (10.0) 60 (9.3) 24 (2.7) 24 (1.8)
 Severe dysfunction, no. (%) 17 (2.8) 17 (2.6) 2 (0.2) 2 (0.2)
 Missing, no. (%) 237 (39.6) 282 (43.6) 537 (61.2) 992 (74.5)
 *  mITT = modified intent-to-treat. 
 †  One patient in study B2412 did not receive artemether-lumefantrine and was excluded from the safety population. 
 ‡ Three patients were ≥ 65 years of age. 
 § Two patients were ≥ 65 years of age. 
 ¶  Study A2401: mean ± SD = 72.9 ± 13.5 kg, range 47–119 kg (66 patients weighed > 70 kg and 5 patients weighed > 100 kg). 
# One patient weighed < 35 kg. 
 **  Defined by creatinine clearance (Cockcroft-Gault/Shull): normal > 80 mL/minute; mild dysfunction ≥ 50–≤ 80 mL/minute; moderate dysfunction ≥ 30–< 50 mL/minute; or severe dysfunction 
< 30 mL/minute. 
 ††  Safety population (n = 1,332). 
 ‡‡  Defined as normal , either total bilirubin ≤ upper limit of normal [ULN], and aspartate aminotransferase [AST] ≤ ULN or total bilirubin ≤ ULN and AST value missing; mild dysfunction, either 
total bilirubin ≤ ULN and AST> ULN, or total bilirubin > ULN – 1.5 × ULN regardless of AST value; moderate dysfunction, total bilirubin > 1.5 – 3 × ULN regardless of AST value; severe dysfunc-
tion, total bilirubin > 3 × ULN regardless of AST value; missing, baseline for total bilirubin is missing regardless of whether AST value is missing. If baseline AST value was missing, baseline alanine 
aminotransferase value was used as per the criteria for AST. 
as serious adverse events. Seven serious adverse events in three 
patients had a suspected relation to AL (abnormal liver func-
tion test results in one patient; disease progression/increased 
bilirubin/increased transaminases/mental impairment/vom-
iting in one patient; and recrudescence in one patient). An 
additional 13 serious adverse events were not suspected to be 
related to AL, and the relationship with AL was unknown for 
the final two events. 
 The overall incidence of adverse events in patients with 
normal renal function or mild impairment was 77.8% (175 
of 225) and 78.3% (112 of 143), respectively. The small num-
ber of patients with moderate renal impairment (n = 10) each 
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reported one or more adverse events. Subgroup analysis by 
hepatic function at baseline showed that the incidence of 
adverse events in adult patients with normal hepatic function 
or mild, moderate, or severe hepatic impairment at baseline 
was 71.9% (120 of 167), 79.3% (96 of 121), 83.3% (50 of 60), 
and 100% (17 of 17), respectively. Many of the adverse events 
that occurred more frequently in the presence of hepatic 
impairment were well-recognized symptoms of malaria. 
 Adverse events in children.  One or more adverse events 
were reported in 970 (72.8%) of 1,332 children; pyrexia 
(28.6%) and cough (22.7%) occurred most frequently ( Table 6 ). 
Adverse events potentially related to hypersensitivity reac-
tions occurred in 4.2% of children; the most frequent reactions 
were rash (2.9%) and dermatitis (0.4%), which showed an 
incidence of 1.1% during days 0–3 of treatment and 1.0% 
during days 4–10 of treatment ( Table 7 ). Nervous system 
disorders were reported as adverse events in 193 patients 
(14.5%), of which headache (n = 168, 12.6%), dizziness (n = 56, 
4.2%), and clonus (n = 11, 0.8%) occurred in > 0.5% of patients. 
All but one case of clonus were reported at a single center 
during protocol-specified routine neurologic examinations in 
which pre-defined signs and symptoms were evaluated, and 
all cases were graded mild. No reports of clonus occurred in 
the population of 899 children in the B2303 study. Ear and 
labyrinth disorders occurred in 6 patients (0.5%), comprising 
ear pain (n = 3), and cerumen impaction, ear pruritus, and 
otorrhea in one patient each. Prolonged QT interval by 
electrocardiogram ECG was reported in one child (0.1%); no 
 Table 3 
 Parasitologic cure rate at day 28 for patients treated with artemether-lumefantrine for uncomplicated  Plasmodium falciparum malaria * 
Group
Adults (all patients) Adults (Study A2401) Children
No./total (%) 95% CI No./total (%) 95% CI No./total (%) 95% CI
mITT population
 Non-PCR corrected 497/599 (83.0) 79.7–85.9 120/162 (74.1) 66.6–80.6 743/863 (86.1) 83.6–88.3
 PCR corrected † 499/598 (83.4) 80.2–86.3 120/162 (74.1) ‡ 66.6–80.6 798/854 (93.4) 91.6–95.0
Evaluable patients
 Non-PCR corrected 494/511 ‡ (96.7) 94.7–98.1 119/124 (96.0) 90.8–98.7 737/823 (89.6) 87.3–91.6
 PCR corrected † 495/510 § ¶ (97.1) 95.2–98.3 119/124 (96.0) 90.8–98.7 792/814 (97.3) 95.9–98.3
 *  CI = confidence interval; mITT = modified intent-to-treat; PCR = polymerase chain reaction. 
 †  PCR analysis was not performed in study A2401. 
 ‡ Two patients were excluded from this analysis after starting antimalarial treatments before day 28 (for reasons other than rescue medication). 
 §  Last observation carried forward: 147 of 162 (90.7%). 
 ¶  One patient was excluded because of a new infection that started before day 28. 
 Table 4 
 Subpopulation analysis of 28-day PCR-corrected parasitologic cure rate (evaluable population) for patients treated with artemether-lumefantrine 
for uncomplicated  Plasmodium falciparum malaria  * 
Characteristic Adults (all patients), no./total (%) Adults (Study A2401), no./total (%) Children, no./total (%)
Age
 > 1 month–≤ 2 years – – 366/377 (97.1)
 2 years–≤ 12 years – – 374/384 (97.4)
 12–≤ 16 years – – 52/53 (98.1)
Body weight (kg)
 5–< 10 – – 210/217 (96.8)
 10–< 15 – – 283/290 (97.6)
 15–< 25 – – 198/204 (97.1)
 25–< 35 – – 50/51 (98.0)
 ≥ 35 – – 50/51 (98.0)
Body weight (kg)
 < 70 – 52/52 (100.0) –
 ≥ 70 – 66/71 (93.0) –
Baseline parasite density, no. (%) † 
 ≤ 100,000/μL 399/408 (97.8) 50/50 (100.0) 718/737 (97.4)
 > 100,000/μL 27/28 (96.4) 0/0 74/77 (96.1)
Renal function, ‡ no. (%)
 Normal 182/188 (96.8) 87/91 (95.6) 169/173 (97.7)
 Mild dysfunction 118/126 (93.7) 27/28 (96.4) 289/302 (95.7)
 Moderate dysfunction 9/9 (100.0) 0/0 174/176 (98.9)
 Severe dysfunction 0/0 0/0 85/86 (98.8)
 Missing 186/187 (99.5) 5/5 (100.0) 75/77 (97.4)
Hepatic function, § no. (%)
 Normal 146/147 (99.3) 57/58 (98.3) 137/141 (97.2)
 Mild dysfunction 101/106 (95.3) 33/35 (94.3) 159/164 (97.0)
 Moderate dysfunction 45/48 (93.8) 16/17 (94.1) 21/22 (95.5)
 Severe dysfunction 9/13 (69.2) 0/0 1/2 (50.0)
 Missing ¶ 194/196 (99.0) 13/14 (92.9) 474/485 (97.7)
 *  PCR = polymerase chain reaction. PCR analysis was not performed in study A2401. 
 †  Data on baseline parasite count not available in parasites/microliter for all patients. 
 ‡ According to creatinine clearance (Cockcroft-Gault/Shull): normal, > 80 mL/minute; mild dysfunction, ≥ 50–≤ 80 mL/minute; moderate dysfunction, ≥ 30–< 50 mL/minute; severe dysfunction, 
< 30 mL/minute. 
 §  Defined as normal, either total bilirubin ≤ upper limit of normal (ULN), and aspartate aminotransferase (AST) ≤ ULN or total bilirubin ≤ ULN and AST value missing; mild dysfunction, either 
total bilirubin ≤ ULN and AST > ULN, or total bilirubin > ULN – 1.5 × ULN regardless of AST value; moderate dysfunction, total bilirubin > 1.5 – 3 × ULN regardless of AST value; severe dysfunc-
tion, total bilirubin > 3 × ULN regardless of AST value; missing, baseline for total bilirubin is missing regardless of whether AST value is missing. If baseline AST value was missing, baseline alanine 
aminotransferase value was used as per the criteria for AST. 
 ¶ Total bilirubin value was missing. 
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other adverse events potentially related to QT prolongation 
were recorded. 
 Four (0.3%) children died. Deaths were caused by severe 
 P. falciparum infection on day 28 (new infection or recrudes-
cence was undetermined) in a patient who was parasite free 
≤ 24 hours and still parasite free on day 13; gastroenteritis on 
day 8 with diarrhea treated with oral rehydration therapy; an 
unspecified infection with pyrexia and dehydration treated 
with quinine, paracetamol, metoclopramide, and amoxicillin; 
and hemorrhage on day 5 after scarification by a traditional 
healer; all deaths were considered unrelated to AL by investi-
gators. Thirty serious adverse events were reported by investi-
gators in 17 patients (1.3%), including  P. falciparum infection 
(7), convulsion (3), pyrexia (2), and anemia (2). None of the 
three cases of convulsion was considered to be related to 
AL; each was reported together with malaria or pyrexia, and 
may have represented febrile convulsions. All other serious 
adverse events were reported in no more than one patient. 
 Table 5 
 Secondary efficacy endpoints (mITT population) for patients treated 
with artemether-lumefantrine for uncomplicated  Plasmodium fal-
ciparum malaria * 
Endpoint Adults (n = 599) Children (n = 877)
Parasite clearance time (hours)
 Median (95% CI) † 42.3 (41.5–43.2) 35.3 (31.7–35.7)
 Mean ± SE † 47.3 ± 1.6 33.2 ± 0.6
 ≤ 48 hours, no. (%) 471 (78.6) 792 (90.3)
 > 48 hours, no. (%) 102 (17.0) 60 (6.8)
 Not achieved, no. (%) 26 (4.3) 25 (2.9)
Fever clearance time (hours)
 Median (95% CI) † 28.5 (22.3–34.0) 7.9 (7.9–8.0)
 Mean ± SE † 37.4 ± 1.8 25.2 ± 1.9
Gametocytes, no. (%)
 Baseline 58/596 (9.7%) 45/877 (5.1%)
 > 0–72 hours 90/597 (15.1%) 90/869 (10.4%)
 > 72 hours–day 7 42/543 (7.7%) 14/828 (1.7%)
 > Day 7 23/554 (4.2%) 8/846 (0.9%)
 *  mITT = modified intent-to teat; CI = confidence interval. The time at which parasite clear-
ance and fever clearance were assessed varied between studies. 
 †  Kaplan Meier estimates; if the last observation is censored, the mean is underestimated. 
 Table 6 
 Adverse events in ≥ 5% of adults or children (safety population) treated 
with artemether-lumefantrine for uncomplicated  Plasmodium fal-
ciparum malaria 
Adverse event Adults (n = 647), no. (%) Children (n = 1,332), no. (%)
Any 557 (86.1) 970 (72.8)
Headache 360 (55.6) 168 (12.6)
Anorexia 260 (40.2) 175 (13.1)
Dizziness 253 (39.1) 56 (4.2)
Asthenia 243 (37.6) 63 (4.7)
Arthralgia 219 (33.8) 39 (2.9)
Myalgia 206 (31.8) 39 (2.9)
Nausea 169 (26.1) 61 (4.6)
Pyrexia 159 (24.6) 381 (28.6)
Chills 147 (22.7) 72 (5.4)
Sleep disorder 144 (22.3) 27 (2.0)
Palpitations 115 (17.8) 24 (1.8)
Vomiting 113 (17.5) 242 (18.2)
Abdominal pain 112 (17.3) 112 (8.4)
Fatigue 111 (17.2) 46 (3.5)
Hepatomegaly 59 (9.1) 75 (5.6)
Splenomegaly 57 (8.8) 124 (9.3)
Diarrhea 46 (7.1) 100 (7.5)
Cough 37 (5.7) 302 (22.7)
Anemia 23 (3.6) 115 (8.6)
 P. falciparum infections 13 (2.0) 224 (16.8)
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One  serious adverse event was reported as having a suspected 
relationship with AL. This event was a case of urticarial rash 
in a four-year-old patient that resolved ≤ 5 days after antihis-
tamine treatment. 
 Seventy-one children (5.3%) left the study prematurely 
because of adverse events. Seventy of these 71 children were 
enrolled in study B2303, in which the protocol specified that 
any patient who required a second replacement dose of study 
drug was to be removed from the study. Four patients stopped 
treatment because of an adverse event other than vomiting. 
These events were  P. falciparum infection plus anemia in one 
patient,  P. falciparum infection plus iron deficiency anemia 
in another patient, a lower respiratory tract infection in one 
patient, and urticaria in one patient as described above. 
 Pediatric patients with mild, moderate, or severe renal 
impairment at baseline had more adverse events than those 
without renal impairment (69.4%, 354 of 510; 77.4%, 226 of 
292; and 92.2%, 94 of 102 versus 60.7%, 198 of 326). Children 
with mild or moderate hepatic impairment had a higher inci-
dence of adverse events than those with normal function 
(77.6%, 132 of 170 and 91.7%, 22 of 24 versus 65.3%, 94 of 
144, respectively) but numbers of patients with moderate (n = 
24) or severe (n = 2) hepatic impairment were low. 
 Laboratory parameters.  Hematogic parameters improved 
during follow-up, which is consistent with resolution of acute 
malaria. Mean values ± SD for hemoglobin level, leukocyte 
count, neutrophil count, and platelet count at baseline were 
12.3 ± 2.5 g/dL, 6.1 ± 2.4 × 10 9 /L, 3.9 ± 1.9 × 10 9 /L, and 130 
± 75 × 10 9 /L, respectively, in adults, and 9.3 ± 1.7 g/dL, 9.3 ± 
3.8 × 10 9 /L, 4.8 ± 2.8 × 10 9 /L, and 181 ± 99 ×10 9 /L in children. 
At days 26–39, the corresponding values were 12.8 ± 1.7 g/dL, 
7.4 ± 2.2 ×10 9 /L, 3.9 ± 1.7 × 10 9 /L, and 231 ± 81 × 10 9 /L in adults 
and 10.4 ± 1.4 g/dL, 9.1 ± 3.3 × 10 9 /L, 3.5 ± 1.9 × 10 9 /L, and 
310 ± 130 × 10 9 /L in children. Renal function (assessed by 
creatinine clearance) increased from baseline and liver 
function values (AST, alanine aminotransferase, and bilirubin) 
decreased from baseline, which is consistent with malaria and 
its resolution. Hemolysis-related adverse events were not 
reported in adults. Four potential hemolysis-related adverse 
events occurred in the pediatric population (0.3%), all of 
which were increased reticulocyte counts. 
 DISCUSSION 
 In this pooled analysis, the largest of its type so far to 
assess AL therapy for the treatment of acute uncomplicated 
 P. falciparum malaria, AL achieved high cure rates and rapid 
symptom relief in adults and children and a good safety and 
tolerability profile. The efficacy of AL was similar for patients 
of all ages in malaria-endemic regions. In the only study of 
travelers from non-endemic regions, analysis was complicated 
by poor follow-up rates, but efficacy of AL also appeared to be 
excellent in the per protocol population. 36 In addition, game-
tocyte carriage decreased markedly from baseline after AL 
administration, which suggested that use of AL can contribute 
to reducing malaria transmission. 
 The observed day 28 PCR-corrected cure rate in evalu-
able patients was approximately 97% in adults and children, 
which exceeded the recommendation of WHO that antima-
larial drugs should show a cure rate of 95%. 1 The cure rate was 
largely unaffected by age, body weight, baseline parasite count, 
or kidney function. A trend to lower cure rates in patients with 
poor baseline liver function may have been an artifact of small 
patient numbers and/or reflect the development of hepatic 
impairment in patients with more severe malaria. Efficacy was 
maintained in the youngest children, who showed a cure rate 
in evaluable children 1 month–2 years of age of approximately 
97%. Importantly, the cure rate was similar in all body weight 
groups in children, despite the difference in doses received on 
a milligram per kilogram basis within each dosing category. 
 Recent reports that showed decreased rates of parasite 
clearance after treatment with artesunate and ACTs in west-
ern Cambodia are of concern. 43, 44 However, if one considers 
this dataset and other recent studies, there is no convincing 
evidence that the efficacy of AL has changed in recent years. 45 
The seven studies included in our analysis spanned the period 
1996–2007, but most adults received AL treatment during 
1996–1999, and the largest studies in children took place during 
2002–2007. Randomized, multicenter trials during 2005–2009 in 
Africa 10, 11, 14, 20, 22, 23, 28, 46, 47 and Asia 24, 25, 48 have each demonstrated a 
PCR-corrected cure rate greater than 95% after AL treatment 
in a variety of populations and settings. These studies have not 
included Cambodia, and it is likely that alterations in artemisi-
nin sensitivity that have led to changes in parasite clearance in 
that country are not yet relevant in most malarious areas. In 
addition, an advantage of the AL combination is that lumefan-
trine has never been used as monotherapy for the treatment of 
malaria, 1 and resistance to this drug in field isolates has not yet 
clearly been demonstrated. 
 Parasite and fever clearance were achieved rapidly after 
treatment with AL in adult and pediatric populations. The 
slower fever clearance observed in study A2401 may have 
been caused by less frequent evaluation in this study and the 
relatively small proportion of patients (approximately 20%) 
who used antipyretics compared with other trials (approxi-
mately 80% in studies A025, A026, and A028). 
 The reduction in gametocytemia after treatment with AL is 
noteworthy. Clearance of gametocytes, the parasite form that 
infects mosquitoes, breaks the cycle of transmission, and thus 
contributes to malaria control. Artemisinins have gametocy-
tocidal properties and reduce gametocyte carriage, 4 and AL 
has shown significantly greater gametocytocidal activity than 
antimalarial drugs other than artemisinin. 16, 27, 49– 51 Randomized 
trials have demonstrated significantly lower rates of gameto-
cytemia after AL treatment compared with oral quinine 47 or 
dihydroartemisinin-piperaquine 50, 52 in patients in Africa with 
uncomplicated  P. falciparum malaria. In our analysis, the pro-
portion of patients with gametocytemia after day 7 decreased 
by more than 50% from baseline in adults and by approxi-
mately 80% in children. Less than 1% of treated children were 
positive for gametocytes after day 7. 
 Our analysis showed no unexpected safety concerns in 
almost 2,000 patients treated with AL. These results are con-
sistent with those of other studies that demonstrated excellent 
safety and tolerability of AL. 11, 28, 53, 54 Most of the frequently 
reported adverse events were typical signs and symptoms of 
malaria. 55 There were few serious adverse events or deaths, 
and serious adverse events were only rarely suspected to be 
related to AL therapy. Urticaria was reported as a severe 
adverse event in only one child and in no adults. Most adverse 
events related to the nervous system, ear, and labyrinth disor-
ders were transient and reversible, and there were no adverse 
events associated with QTc prolongation. Hemolysis-related 
adverse events were absent in adults and rare in the  pediatric 
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population (reticulocyte count increase in 0.3% of patients, 
in parallel with an increase in hemoglobin level) with the few 
reported events deemed unrelated to AL treatment. Thus, AL 
treatment does not appear to trigger hemolysis, consistent with 
the findings reported by Premji and others 56 in a randomized, 
double-blind trial of patients in Africa with uncomplicated  P. 
falciparum malaria. 
 Unforeseen differences were not observed in the adverse 
event profile or laboratory results between subgroups. The 
higher rate of adverse events reported in patients with hepatic 
or renal impairment is likely to reflect more severe malaria 
in these groups. Cough was more frequent in children than in 
adults, which is not unexpected because respiratory infections 
are common in children in Africa with malaria. 57 Previous 
reports have suggested that cough is unlikely to be causally 
related to artemesinin-based therapy, and the fact that time to 
onset of cough was relatively evenly distributed throughout 
the duration of the studies suggests that cough was probably 
not related either to malaria or to AL treatment. The higher 
rates of headache and dizziness in older children compared 
with young children and infants were probably caused by 
increased ability to report symptoms. 
 This pooled analysis had some limitations. First, as an 
unplanned pooling of data, the seven studies used various 
schedules for assessment and procedures for reporting adverse 
events. Accordingly, the reported rates of events cannot reli-
ably be compared between trials. However, it is unlikely that 
this limitation impaired detection of any novel safety signals. 
Second, three of the seven studies were undertaken before 
2000, i.e., more than 10 years ago, although there is no evidence 
to suggest that the efficacy and safety of AL have changed in 
the past decade 45 because there are numerous more recent ran-
domized trials confirming its therapeutic effect. 10, 11, 14, 20, 22– 25, 28, 46– 48 
Third, five studies were open-label and two were single-arm 
studies. The open-label designs were used because of the dif-
ficulty of using double-blind methods, which would have 
required large numbers of tablets in these acutely ill patients. 
Some studies were non-comparative, either because no suit-
able comparator was available at the time or because inclu-
sion of a control arm would have greatly increased the time 
required for recruitment. Perhaps less importantly, but still of 
relevance, supervision of the AL doses was not specified for 
two trials. Fourth, no adult patients were recruited in Africa, 
but the studies in children were predominantly in African chil-
dren. However, there is no evidence in the literature of a dif-
ference in PCR-corrected AL cure rates between geographic 
regions. 60 Fifth, no children were included in the only study of 
non-immune persons. Sixth, laboratory data collection was rel-
atively limited and varied between studies, and sampling and 
analysis were often restricted by local facilities. Sixth, because 
studies were derived from the Novartis database to permit full 
access to data, it must be remembered that all trials were sup-
ported by Novartis as part of the registration activity for AL in 
the United States, Europe, Switzerland, and malaria-endemic 
countries. 
 In conclusion, in this pooled analysis of almost 2,000 
patients, the PCR-corrected 28-day cure rate for AL treat-
ment of uncomplicated  P. falciparum malaria exceeded 95% 
in adults and children, and showed a good safety and tolera-
bility profile and rapid reduction in gametocytemia. Although 
data for non-immune persons remain limited, our findings 
are consistent with the recommendation that AL be used as 
first-line treatment of uncomplicated  P. falciparum malaria in 
patients of all ages, whether they are semi-immune residents 
or non-immune visitors in malaria endemic or non-endemic 
regions. 
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